Cipla Limited

INR 7,073

mance1 in focused markets; upward operating profitability trajectory Revenue EBITDA PAT Q3FY25 INR 7,073 Cr 8% (YoY) INR 1,989 Cr (YoY) 16% 184 bps INR 1,571 Cr (YoY) 50% 617 bps 28.1% of Revenue

8%

sed markets; upward operating profitability trajectory Revenue EBITDA PAT Q3FY25 INR 7,073 Cr 8% (YoY) INR 1,989 Cr (YoY) 16% 184 bps INR 1,571 Cr (YoY) 50% 617 bps 28.1% of Revenue 22.2

INR 1,989

; upward operating profitability trajectory Revenue EBITDA PAT Q3FY25 INR 7,073 Cr 8% (YoY) INR 1,989 Cr (YoY) 16% 184 bps INR 1,571 Cr (YoY) 50% 617 bps 28.1% of Revenue 22.2% of Revenue Busin

16%

ofitability trajectory Revenue EBITDA PAT Q3FY25 INR 7,073 Cr 8% (YoY) INR 1,989 Cr (YoY) 16% 184 bps INR 1,571 Cr (YoY) 50% 617 bps 28.1% of Revenue 22.2% of Revenue Business Performanc

184 bps

ability trajectory Revenue EBITDA PAT Q3FY25 INR 7,073 Cr 8% (YoY) INR 1,989 Cr (YoY) 16% 184 bps INR 1,571 Cr (YoY) 50% 617 bps 28.1% of Revenue 22.2% of Revenue Business Performance Snapsh

INR 1,571

rajectory Revenue EBITDA PAT Q3FY25 INR 7,073 Cr 8% (YoY) INR 1,989 Cr (YoY) 16% 184 bps INR 1,571 Cr (YoY) 50% 617 bps 28.1% of Revenue 22.2% of Revenue Business Performance Snapshot One Indi

50%

BITDA PAT Q3FY25 INR 7,073 Cr 8% (YoY) INR 1,989 Cr (YoY) 16% 184 bps INR 1,571 Cr (YoY) 50% 617 bps 28.1% of Revenue 22.2% of Revenue Business Performance Snapshot One India North Ameri

617 bps

A PAT Q3FY25 INR 7,073 Cr 8% (YoY) INR 1,989 Cr (YoY) 16% 184 bps INR 1,571 Cr (YoY) 50% 617 bps 28.1% of Revenue 22.2% of Revenue Business Performance Snapshot One India North America Sout

28.1%

3FY25 INR 7,073 Cr 8% (YoY) INR 1,989 Cr (YoY) 16% 184 bps INR 1,571 Cr (YoY) 50% 617 bps 28.1% of Revenue 22.2% of Revenue Business Performance Snapshot One India North America South Afric

22.2%

8% (YoY) INR 1,989 Cr (YoY) 16% 184 bps INR 1,571 Cr (YoY) 50% 617 bps 28.1% of Revenue 22.2% of Revenue Business Performance Snapshot One India North America South Africa Private Emerging

INR 3,146

s Performance Snapshot One India North America South Africa Private Emerging Markets & Europe INR 3,146 Cr 10% (YoY) $ 226 Mn 2% (YoY) ZAR 1,196 Mn 8% (YoY) $ 98 Mn 20% (YoY) Q3FY25 Chronic mix2

10%

Snapshot One India North America South Africa Private Emerging Markets & Europe INR 3,146 Cr 10% (YoY) $ 226 Mn 2% (YoY) ZAR 1,196 Mn 8% (YoY) $ 98 Mn 20% (YoY) Q3FY25 Chronic mix2 improve

Cipla is included in

1

Registered Office

1

Cipla is included in

• DJSI World Index 2024 • DJSI Emerging Market Index 2024 • Achieved 1st place in India in the Drug and Pharma sector Cipla meets its Zero Waste to Land Fill goal a year in advance • 36 operational Units & R&D Centre in India certified for ZWTL 13% reduction in freshwater withdrawal compared to FY20 52% of water recycled as percentage of water withdrawal 28% renewable energy in energy mix compared to 9% in FY20 Ciprofloxacin is now AMR certified by BSI • Ciprofloxacin made at Indore is AMR compliant. Certified by BSI • Product meets AMR alliance’s Antibiotic Manufacturing standard 2022 Note: Boundary is India Manufacturing operations 13 Consolidated Profit and Loss statement summary (Reported) Particulars Q3 FY25 Q3 FY24 INR Cr Revenue from sale of products Other operating income Income from operations Material cost Employee benefits expense Other expenses Total expenses Finance costs Depreciation, impairment and amortisation expense Other income Profit before exceptional items and tax

Registered Office

Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Diksha Maheshwari Investor.Relations@cipla.com For more information please visit www.cipla.com 16